|Bid||21.16 x 800|
|Ask||21.25 x 800|
|Day's Range||20.47 - 21.51|
|52 Week Range||6.75 - 23.05|
|Beta (3Y Monthly)||-0.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.58|
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Codexis is on pace to become the first publicly-traded synthetic biology company to deliver consistent operating profits. Investors should take note.
In 2012 John Nicols was appointed CEO of Codexis Inc (NASDAQ:CDXS). First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a snap Read More...
Codexis (CDXS) delivered earnings and revenue surprises of 100.00% and 15.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had a loss of 4 cents. Earnings, adjusted for stock option expense and non-recurring costs, were less than 1 cent on a per-share ...
Total revenues increase 70% to $16.9 million driven by higher product revenue and R&D revenue across an increased number of customers Conference call begins at 4:30 p.m..
Codexis, Inc. (CDXS), a leading protein engineering company, announces top-line results from its Phase 1a single ascending-dose study in healthy volunteers with CDX-6114, its orally administered enzyme candidate for the potential treatment of the metabolic disorder phenylketonuria (PKU). The randomized, double-blind, placebo-controlled Phase 1a study evaluated the safety and tolerability of CDX-6114 in 32 healthy volunteers evenly divided into four cohorts. Each cohort was administered a single dose of CDX-6114 at increasingly higher dose levels.
REDWOOD CITY, Calif., Nov. 07, 2018 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment.
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., Nov. 01, 2018 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report third quarter 2018 financial results.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Both stocks have gained over 140% in the last year alone. Both are looking forward to growth from innovative sweetener ingredients. One doesn't belong in your portfolio.
REDWOOD CITY, Calif., Oct. 01, 2018-- Codexis, Inc., a leading protein engineering company, announces the appointment of Claus Ladefoged as Director, Enzyme Business Development. Ladefoged has extensive ...
The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor
There are still winners on the index across industries that are easily surviving the worst start to September and have a solid Zacks Rank #1 (Strong Buy) or 2 (Buy).
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...
Investors looking for fast-growing stocks in an expensive market might want to follow the lead of Mike Balkin and Ward Sexton, managers of the superstar William Blair Small Cap Growth fund, which has outpaced 94% of small-cap growth funds tracked by Morningstar.
W.W. Grainger (GWW) will gain from its investment in e-commerce and digital capabilities as well as executing supply chain management actions and efforts to strengthen relationships with customers.
Codexis (CDXS) delivered earnings and revenue surprises of 83.33% and 14.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Redwood City, California-based company said it had a loss of 7 cents per share. Losses, adjusted for stock option expense and non-recurring costs, came to 2 cents per share. The producer of custom ...